The University of New Mexico
Welcome,         Profile    Billing    Logout  
 23 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Le, Anh
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
Witkiewitz, Katie
NCT04416711: Alcohol And Sexual Risk Behavior

Recruiting
N/A
190
US
Personalized Feedback, Cognitive Skills Training, Services As Usual
Arizona State University, University of Iowa, University of New Mexico
Sexually Aggressive Behavior, Risky Sexual Behavior, Heavy Episodic Drinking
01/25
01/25
POSITIVE, NCT04648228: Pain and Opioids: Integrated Treatment In Veterans

Active, not recruiting
N/A
157
US
ACT+MBRP, Education control
University of New Mexico, National Institute on Drug Abuse (NIDA), University of Utah, Johns Hopkins University, Duke University, Vanderbilt University, Biomedical Research Institute of New Mexico, Seattle Institute for Biomedical and Clinical Research, Queen's University, Belfast, University of California, San Francisco, San Francisco VA Health Care System
Chronic Pain, Opioid-use Disorder, Opioids; Harmful Use
12/25
01/26
ABQ TREAT, NCT03842670: Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Treatment for Alcohol Use Disorder

Active, not recruiting
N/A
110
US
Cognitive Behavior Therapy, Mindfulness Based Relapse Prevention
University of New Mexico, The Mind Research Network
Alcohol Use Disorder, Alcohol Abuse, Alcohol Drinking, Alcohol Dependence
03/25
03/25
HOPE, NCT05571917: Healing Opioid Misuse and Pain Through Engagement () Trial

Recruiting
N/A
160
US
Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP), Enhance Usual Care (EUC)
University of New Mexico, University of Michigan, Wake Forest University, National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Chronic Pain
12/25
12/26
THRIVE, NCT06074341: TeleHealth Resources for IndiVidualizEd Goals () in Alcohol Recovery Study

Recruiting
N/A
430
US
Mindfulness-based relapse prevention, Online Mutual Support Groups
University of New Mexico, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol Drinking, Alcohol-Related Disorders
01/28
07/28
Meriwether, Kate V
VULVIE, NCT04951206: Fractionated CO2 Laser with and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

Recruiting
4
184
US
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment, Clobetasol
Medstar Health Research Institute, Patty Brisben Foundation For Women's Sexual Health, Society of Gynecologic Surgeons
Vulvar Lichen Sclerosus
03/25
06/25
MYPAICE, NCT04820855: Mindfulness and Yoga for Pain With Interstitial Cystitis Evaluation

Completed
N/A
97
US
Treatment, Mind/Body Therapy, Usual Cares, Standard Cares
University of New Mexico
Interstitial Cystitis
09/23
12/23
INTENSE, NCT05309993: INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

Recruiting
N/A
130
US
PTNS, Posterior Tibial Nerve Stimulation, TENS, transcutaneous electrical nerve stimulation
University of New Mexico
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urge Incontinence, Urinary Bladder, Overactive, Urinary Incontinence, Urge
12/26
12/26
NCT04772131: Desara ® One Single Incision Sling 522 Study

Recruiting
N/A
300
US
Desara® One Single Incision Sling, Desara® Blue Transobturator Sling
Caldera Medical, Inc.
Stress Urinary Incontinence
11/26
11/26
Brown-Glaberman, Ursa
Precision Promise, NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
TMIST, NCT03233191: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Active, not recruiting
3
108508
Europe, Canada, US, RoW
Digital Mammography, Full Field Digital Mammography, FFDM, Digital Tomosynthesis Mammography, DBT, Digital Breast Tomosynthesis, Digital Tomosynthesis of the Breast, Laboratory Biomarker Analysis, Biomarker analysis, genetic analysis, PAM50
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI), Canadian Cancer Trials Group (CCTG)
Breast Screening
12/28
12/30
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
NCT04137107: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer

Active, not recruiting
2/3
220
US, RoW
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Stage II Colorectal Cancer AJCC V8, Stage III Colorectal Cancer AJCC V8
02/26
12/26
PLATINUM, NCT06115499: The Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Recruiting
2/3
100
US
Nab paclitaxel, ABI-007, Abraxane, Albumin-bound Paclitaxel, Protein-bound Paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen Collection
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC V8
01/29
12/29
EA2197, NCT04559139: Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Recruiting
2/3
186
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Lymphadenectomy, excision of the lymph node, Lymph Node Dissection, lymph node excision, Partial Hepatectomy, partial excision of liver, subtotal hepatectomy
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
06/29
06/29
DARE, NCT04567420: DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Recruiting
2
70
US
Palbociclib, IBRANCE, Fulvestrant, Faslodex, Adjuvant Therapy, Standard of Care
Criterium, Inc.
Breast Cancer
12/27
12/27
ComboMATCH Treatment Trial, NCT05564403: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A )

Recruiting
2
66
US
Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669
National Cancer Institute (NCI)
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
01/26
01/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
NCT05638295: Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Recruiting
2
105
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
12/25
12/25
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting
2
154
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Active, not recruiting
2
138
Europe, US
Computed Tomography, CAT, CAT scan, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
08/27
08/27
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Active, not recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
07/24
10/25
PE-CGS, NCT06207864: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

Recruiting
N/A
1001
US
Biospecimen Collection, Biological Sample Collection, Specimen Collection, Return of Results, Survey Administration
New Mexico Cancer Care Alliance, National Cancer Institute (NCI)
Malignant Neoplasm
12/28
12/30
NCT03568448: Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

Recruiting
N/A
30
US
Response monitoring (no intervention)
New Mexico Cancer Care Alliance
HER2 Negative Breast Cancer
01/20
12/24
SWOG-S1703, NCT03723928: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Recruiting
N/A
739
US, RoW
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, STMDDM, Quality-of-Life Assessment, Quality of Life Assessment, Anxiety Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
12/30
12/36
Ford, Corey
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting
2
450
Europe, Canada, US, RoW
IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm
Immunic AG
Multiple Sclerosis
01/25
01/25
McCrady, Barbara
ABQ TREAT, NCT03842670: Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Treatment for Alcohol Use Disorder

Active, not recruiting
N/A
110
US
Cognitive Behavior Therapy, Mindfulness Based Relapse Prevention
University of New Mexico, The Mind Research Network
Alcohol Use Disorder, Alcohol Abuse, Alcohol Drinking, Alcohol Dependence
03/25
03/25
Melendres-Groves, Lana
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
Vaccarro, Christine
VULVIE, NCT04951206: Fractionated CO2 Laser with and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

Recruiting
4
184
US
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment, Clobetasol
Medstar Health Research Institute, Patty Brisben Foundation For Women's Sexual Health, Society of Gynecologic Surgeons
Vulvar Lichen Sclerosus
03/25
06/25
McCune, Tara
ABQ TREAT, NCT03842670: Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological Treatment for Alcohol Use Disorder

Active, not recruiting
N/A
110
US
Cognitive Behavior Therapy, Mindfulness Based Relapse Prevention
University of New Mexico, The Mind Research Network
Alcohol Use Disorder, Alcohol Abuse, Alcohol Drinking, Alcohol Dependence
03/25
03/25
Majeed, Umair
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Hourglass Nov 2024 - Dec 2024 : Initial data from at least one additional arm of the Phase 2a portion
Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruiting
1/2
158
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
RAIDEN, NCT06058663: Radioembolization with Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
1
18
US
Angiography, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Imjudo, Ticilimumab, Tremelimumab-actl, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization
Mayo Clinic, National Cancer Institute (NCI)
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC V8, Stage IV Intrahepatic Cholangiocarcinoma AJCC V8, Unresectable Intrahepatic Cholangiocarcinoma
11/25
11/25
NCT04328740: Phase 1 Study of Oral TP-1454

Active, not recruiting
1
31
US
TP-1454 monotherapy
Sumitomo Pharma America, Inc.
Advanced Solid Tumor, Anal Cancer
03/25
05/25

Download Options